Substance abuse treatment refers to programs and activities that are aimed at managing substance dependence and support long-term sobriety and recovery. Substance abuse disorder which is also known as addiction, involves the compulsive or uncontrollable use of harmful and addictive substances despite their negative impact. Common substances of abuse include alcohol, opioids, cannabis, cocaine, and methamphetamines. Some key signs of substance abuse disorder include the inability to reduce intake, experiencing cravings, and having withdrawal symptoms when not using. Those suffering from addiction often experience impaired control, social problems, risky use, and sometimes even physical dependence. Substance abuse treatment aims to address the biological, psychological, social, and behavioral aspects of addiction through therapeutic interventions, counseling, medication, and community support programs. The rise in substance abuse rates globally is fueling demand for effective treatment options.
Global substance abuse treatment market is driven by the rising prevalence of substance abuse disorders, increasing awareness regarding treatment availability, favorable regulations and reimbursement policies, and the launch of novel medication-assisted treatment products. However, the market growth can be restrained by social stigmas that are associated with addiction, lack of access to treatment facilities in low-income regions, and non-compliance issues with treatment protocols. The development of digital therapeutic solutions, integrated care models, targeted therapies for specific addictions, and expansion to emerging markets present key opportunities for the market players. Geographically, North America dominates the market due to advanced healthcare infrastructure and awareness. However, the Asia Pacific region is expected to offer lucrative growth prospects during the forecast period.
- This report provides an in-depth analysis of the global substance abuse treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2025–2032), considering 2024 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global substance abuse treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Indivior PLC, Pfizer, Inc., Johnson & Johnson Inc., Alkermes., Mallinckrodt Pharmaceuticals, Teva Pharmaceuticals, Inc., Par Pharmaceutical, Inc., USWM, LLC, Valeant Pharmaceuticals, Greenyard Pharmaceutical Ltd. Cipla Health Limited. Perrigo, Haleon Group of Companies, Ventus Medical, Glenmark and other prominent players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global substance abuse treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global substance abuse treatment market.
- Alcohol
- Opioids (e.g., heroin, prescription painkillers)
- Tobacco/nicotine
- Cocaine
- Marijuana
- Methamphetamines
- Other illicit drugs (Benzodiazepines, etc.)
- Opioid
- Methadone
- Buprenorphine
- Extended-release naltrexone
- Lofexidine
- Nicotine
- Nicotine replacement therapies (available as a patch, inhaler, or gum)
- Bupropion
- Varenicline
- Alcohol
- Naltrexone
- Disulfiram
- Acamprosate
- Tobacco
- Others (Topiramate, Modafinil, etc.)
- Adolescents
- Adults
- Geriatric
- Outpatient Treatment
- Outpatient Clinics
- Private Practices
- Inpatient Treatment
- Rehabilitation Centers
- Hospitals
- Residential Treatment Facilities
- Detoxification Centers
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Indivior PLC
- Pfizer, Inc.
- Johnson & Johnson Inc.
- Mallinckrodt Pharmaceuticals
- Teva Pharmaceuticals, Inc.
- Par Pharmaceutical, Inc.
- USWM, LLC
- Valeant Pharmaceuticals
- Greenyard Pharmaceutical Ltd.
- Cipla Health Limited
- Perrigo
- Haleon Group of Companies
- Ventus Medical
- Glenmark
- Other Prominent Players
